论文部分内容阅读
选取在我院T_2DM患者50例,随机分为对照组25例实施二甲双胍联合格列美脲治疗,观察组25例采用二甲双胍联合维格列汀治疗。结果:治疗前,两组血糖差异无统计学意义(P>0.05);治疗后,观察组HbA_(1c)、2hPG较对照组明显改善(P<0.05);观察组24h平均血糖(MBG)、平均血糖波动幅度(MAGE)较对照组明显降低,血糖达标时间明显缩短,(P<0.05)。结论维格列汀联合二甲双胍治疗,可降低患者血糖水平,且血糖波动较小。
Fifty patients with T_2DM in our hospital were randomly divided into control group (n = 25) and metformin combined with glimepiride (n = 25). Metformin and vildagliptin were used in the observation group (n = 25). Results: Before treatment, there was no significant difference in blood glucose between the two groups (P> 0.05). After treatment, HbA 1c and 2hPG in the observation group were significantly improved (P <0.05) Mean blood glucose fluctuation (MAGE) was significantly lower than the control group, blood glucose compliance time was significantly shorter, (P <0.05). Conclusion Vildagliptin combined with metformin can reduce blood glucose levels in patients, and blood glucose fluctuations smaller.